Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan.

OBJECTIVES To evaluate the long term immunity provided by a universal hepatitis B vaccination program in infancy and the booster effect on school age children who had no protective antibody titers to hepatitis B surface antigen. METHODS We conducted a community-based seroepidemiologic study of 1337 healthy 7-year-old children in Taiwan one decade after the implementation of a mass hepatitis B vaccination program. A booster vaccination was suggested for noncarrier children who did not have protective titers of surface antibody. Serologic responses and infection rates were compared with those of the nonboostered children. In a nonselected group of 39 volunteer noncarrier vaccinees, quantitative serologic response was determined before, 1 month after a booster vaccination and 1 year later. RESULTS A total of 572 children (42.8%) had low concentrations of surface antibody, and 9 were hepatitis B surface antigen carriers (0.7%). Eighty-two percent of "nonprotected" vaccinees showed immunologic memory to a booster dose and developed protective antibody titers 1 month later; 60.6% maintained protective titers 1 year later. The frequency of new hepatitis B virus infection was similar for those who received a booster and those who did not as investigated by the core antibody seroconversion during 1-year follow-up. However, the risk was low, with annual incidences of <1% in both groups, and none became chronic carriers. CONCLUSION According to these data a universal vaccination program in infancy provides adequate protection against hepatitis B virus infection for school age children and a booster vaccination is not recommended.

[1]  M. Lai,et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. , 1997, The New England journal of medicine.

[2]  H. Hsu,et al.  Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. , 1996, JAMA.

[3]  G. Calandra,et al.  Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. , 1996, Vaccine.

[4]  D. West,et al.  Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. , 1994, The Pediatric infectious disease journal.

[5]  E. Yeoh,et al.  Five‐year follow‐up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma‐derived vaccine in children: Immunogenicity and anamnestic responses , 1993, Hepatology.

[6]  R. Smego,et al.  A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  H. Margolis Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. , 1993, The Journal of infectious diseases.

[8]  P. Toy,et al.  Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. , 1992, Pediatrics.

[9]  J. L. Montagne,et al.  Universal hepatitis B immunization , 1992 .

[10]  H. Hsu,et al.  Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: Five years after a mass hepatitis B vaccination program , 1991, Journal of medical virology.

[11]  N. Day,et al.  Scheduling of revaccination against hepatitis B virus , 1991, The Lancet.

[12]  H. Inskip,et al.  Vaccination aginst chronic viral carriage in The Gambia , 1991, The Lancet.

[13]  J. Waldon,et al.  Very low dose hepatitis B vaccination in the newborn: Anamnestic response to booster at four years , 1990, Journal of medical virology.

[14]  J. Sung,et al.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. , 1987, JAMA.

[15]  S. Hadler,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.

[16]  H. Hsu,et al.  Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan , 1986, Journal of medical virology.

[17]  M Gesemann,et al.  Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. , 1995, Vaccine.

[18]  P. McIntyre Hepatitis B vaccination follow-up. , 1995, Lancet.

[19]  M. Kane Global programme for control of hepatitis B infection. , 1995, Vaccine.

[20]  B. Yvonnet,et al.  Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. , 1994, Journal of hepatology.

[21]  H. Hsu,et al.  Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. , 1993, Vaccine.

[22]  F. Salvá,et al.  A 7-year follow-up of newborns vaccinated against hepatitis B. , 1993, Vaccine.

[23]  C. Azzari,et al.  Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses. , 1991, Vaccine.

[24]  F. Deinhardt,et al.  Persistence of specific antibodies after hepatitis B vaccination. , 1988, Journal of hepatology.